HOME > BUSINESS
BUSINESS
- Ono, Univ. of Tokyo Sign Joint Research Agreement for Drug Discovery Target Identification
September 29, 2011
- MTPC to Start PIII Trial for Telaprevir in China Early 2012
September 29, 2011
- NBI Releases Latest PMS Results for Prazaxa
September 28, 2011
- Rivaroxaban Recommended for Approval in EU: Bayer
September 28, 2011
- Astellas Pharma Debuts on DJSI Asia Pacific Index
September 28, 2011
- Kowa, NanoCarrier Announce License Agreement for Epirubicin Micelle
September 28, 2011
- Dry Eye Treatment Mucosta Ophthalmic Suspension Approved: Otsuka
September 27, 2011
- Teva to Resolve Joint Venture with Kowa, Acquire 100% Stake in Teva-Kowa
September 27, 2011
- Japan’s First Oral MS Treatment Imusera/Gilenya Approved: MTPC/Novartis
September 27, 2011
- Prazaxa Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
September 27, 2011
- Breast Cancer Treatment Faslodex Approved: AZ
September 27, 2011
- BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end
September 27, 2011
- COPD Treatment NVA237 Filed in Europe by Novartis: Sosei
September 27, 2011
- Novartis Announces New PIII Data for Inhaled Therapy NVA237 at ERS Congress
September 27, 2011
- Daiichi Sankyo Unable to Ship 2.36 million Vials of Flu Vaccine Due to Virus Contamination
September 26, 2011
- OncoTherapy To Receive Milestone Payment following Submission of PI Clinical Trial Certificate
September 26, 2011
- Shanghai Genomics Receives New Drug Certificate for the Treatment of IPF in China
September 26, 2011
- Astellas: OAB Treatment Betanis Tablets
September 26, 2011
- Ono/Astellas: Once-Every-Four-Weeks Formulation of Recalbon, Bonoteo
September 26, 2011
- MTPC, Janssen Pharma Launch RA Treatment Simponi
September 26, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…